Summary

The global Targeted Protein Degradation Technology market size was US$ 133 million in 2025 and is forecast to reach a readjusted size of US$ 422 million by 2032 with a CAGR of 18.3% during the forecast period 2026-2032.
Targeted protein degradation technology involves the design and development of small molecules or biologics that selectively bind to specific proteins within cells and mark them for degradation by the cell's natural protein degradation machinery, such as the ubiquitin-proteasome system or lysosomes. This approach enables the removal of disease-causing or undesirable proteins, including those considered "undruggable" by traditional small molecule inhibitors, by harnessing the body's own degradation pathways. Typically, targeted protein degraders consist of a ligand that binds to the target protein, a linker, and a component that recruits the cellular degradation machinery. This technology holds promise for the treatment of various diseases, including cancer and genetic disorders, by targeting proteins involved in disease pathways with high specificity and efficacy.
Targeted protein degradation (TPD) technology is experiencing rapid growth and increasing interest across the biopharmaceutical industry, driven by its ability to address previously "undruggable" targets and offer novel therapeutic strategies for cancer, neurodegenerative diseases, and autoimmune disorders. The market is characterized by a surge in strategic partnerships, licensing deals, and R&D investments from both established pharmaceutical companies and emerging biotech firms. Key technological platforms—such as PROTACs (proteolysis-targeting chimeras), molecular glues, and autophagy-based degraders—are progressing through clinical pipelines, with several candidates entering early-phase trials. As the field matures, advancements in degrader design, improved target specificity, and favorable regulatory developments are expected to accelerate adoption and expand therapeutic applications.
The global Targeted Protein Degradation Technology market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company:
Arvinas
C4 Therapeutics
Kymera Therapeutics
Nurix
Pfizer
Novartis
MSD
Foghorn Therapeutics
Dialectic Therapeutics
Accutar Biotech
Cullgen
Bristol-Myers Squibb
Monte Rosa Therapeutics
Proxygen
Dunad Therapeutics
Astellas
Origami Therapeutics
NEOsphere Biotechnologies
Ubiquigent
Kangpu Biopharmaceuticals
Ranok Therapeutics
BeiGene
Hinova Pharma
Haisco Pharmaceutical
CTTQ
Segment by Type
PROTAC
Molecular Glues
Other Ubiquitin-Proteasome System Technologies
Lysosomal System Technologies
Segment by Application
Prostate Cancer
Breast Cancer
Lymphoma
Others
By Region
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Markets
North America
Europe
China
Japan
(Additional regions can be customized based on client needs.)
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)
Chapter 2: Quantitative analysis of Targeted Protein Degradation Technology market size and growth potential at global, regional, and country levels
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities
Chapter 6: Regional revenue breakdown by company, type, application and customer
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Targeted Protein Degradation Technology value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 PROTAC
1.2.3 Molecular Glues
1.2.4 Other Ubiquitin-Proteasome System Technologies
1.2.5 Lysosomal System Technologies
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Prostate Cancer
1.3.3 Breast Cancer
1.3.4 Lymphoma
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered

2 Global Growth Trends
2.1 Global Targeted Protein Degradation Technology Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global Targeted Protein Degradation Technology Market Share by Revenue, by Region (2021-2026)
2.4 Global Targeted Protein Degradation Technology Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America Targeted Protein Degradation Technology Market Size and Prospective (2021-2032)
2.5.2 Europe Targeted Protein Degradation Technology Market Size and Prospective (2021-2032)
2.5.3 China Targeted Protein Degradation Technology Market Size and Prospective (2021-2032)
2.5.4 Japan Targeted Protein Degradation Technology Market Size and Prospective (2021-2032)

3 Breakdown Data by Type
3.1 Global Targeted Protein Degradation Technology Historical Market Size by Type (2021-2026)
3.2 Global Targeted Protein Degradation Technology Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of Targeted Protein Degradation Technology

4 Breakdown Data by Application
4.1 Global Targeted Protein Degradation Technology Historical Market Size by Application (2021-2026)
4.2 Global Targeted Protein Degradation Technology Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in Targeted Protein Degradation Technology Applications

5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Targeted Protein Degradation Technology Players by Revenue (2021-2026)
5.1.2 Global Targeted Protein Degradation Technology Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Targeted Protein Degradation Technology Revenue
5.4 Global Targeted Protein Degradation Technology Market Concentration Analysis
5.4.1 Global Targeted Protein Degradation Technology Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Targeted Protein Degradation Technology Revenue in 2025
5.5 Global Key Players of Targeted Protein Degradation Technology Head Offices and Areas Served
5.6 Global Key Players of Targeted Protein Degradation Technology, Product and Application
5.7 Global Key Players of Targeted Protein Degradation Technology, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America Targeted Protein Degradation Technology Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America Targeted Protein Degradation Technology Market Size by Type (2021-2026)
6.1.2.2 North America Targeted Protein Degradation Technology Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America Targeted Protein Degradation Technology Market Size by Application (2021-2026)
6.1.3.2 North America Targeted Protein Degradation Technology Market Share by Application (2021-2026)
6.1.4 North America Targeted Protein Degradation Technology Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe Targeted Protein Degradation Technology Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Targeted Protein Degradation Technology Market Size by Type (2021-2026)
6.2.2.2 Europe Targeted Protein Degradation Technology Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Targeted Protein Degradation Technology Market Size by Application (2021-2026)
6.2.3.2 Europe Targeted Protein Degradation Technology Market Share by Application (2021-2026)
6.2.4 Europe Targeted Protein Degradation Technology Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 China Market: Players, Segments, Downstream and Major Customers
6.3.1 China Targeted Protein Degradation Technology Revenue by Company (2021-2026)
6.3.2 China Market Size by Type
6.3.2.1 China Targeted Protein Degradation Technology Market Size by Type (2021-2026)
6.3.2.2 China Targeted Protein Degradation Technology Market Share by Type (2021-2026)
6.3.3 China Market Size by Application
6.3.3.1 China Targeted Protein Degradation Technology Market Size by Application (2021-2026)
6.3.3.2 China Targeted Protein Degradation Technology Market Share by Application (2021-2026)
6.3.4 China Targeted Protein Degradation Technology Major Customers
6.3.5 China Market Trends and Opportunities
6.4 Japan Market: Players, Segments, Downstream and Major Customers
6.4.1 Japan Targeted Protein Degradation Technology Revenue by Company (2021-2026)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Targeted Protein Degradation Technology Market Size by Type (2021-2026)
6.4.2.2 Japan Targeted Protein Degradation Technology Market Share by Type (2021-2026)
6.4.3 Japan Market Size by Application
6.4.3.1 Japan Targeted Protein Degradation Technology Market Size by Application (2021-2026)
6.4.3.2 Japan Targeted Protein Degradation Technology Market Share by Application (2021-2026)
6.4.4 Japan Targeted Protein Degradation Technology Major Customers
6.4.5 Japan Market Trends and Opportunities

7 Key Player Profiles
7.1 Arvinas
7.1.1 Arvinas Company Details
7.1.2 Arvinas Business Overview
7.1.3 Arvinas Targeted Protein Degradation Technology Introduction
7.1.4 Arvinas Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.1.5 Arvinas Recent Development
7.2 C4 Therapeutics
7.2.1 C4 Therapeutics Company Details
7.2.2 C4 Therapeutics Business Overview
7.2.3 C4 Therapeutics Targeted Protein Degradation Technology Introduction
7.2.4 C4 Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.2.5 C4 Therapeutics Recent Development
7.3 Kymera Therapeutics
7.3.1 Kymera Therapeutics Company Details
7.3.2 Kymera Therapeutics Business Overview
7.3.3 Kymera Therapeutics Targeted Protein Degradation Technology Introduction
7.3.4 Kymera Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.3.5 Kymera Therapeutics Recent Development
7.4 Nurix
7.4.1 Nurix Company Details
7.4.2 Nurix Business Overview
7.4.3 Nurix Targeted Protein Degradation Technology Introduction
7.4.4 Nurix Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.4.5 Nurix Recent Development
7.5 Pfizer
7.5.1 Pfizer Company Details
7.5.2 Pfizer Business Overview
7.5.3 Pfizer Targeted Protein Degradation Technology Introduction
7.5.4 Pfizer Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.5.5 Pfizer Recent Development
7.6 Novartis
7.6.1 Novartis Company Details
7.6.2 Novartis Business Overview
7.6.3 Novartis Targeted Protein Degradation Technology Introduction
7.6.4 Novartis Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.6.5 Novartis Recent Development
7.7 MSD
7.7.1 MSD Company Details
7.7.2 MSD Business Overview
7.7.3 MSD Targeted Protein Degradation Technology Introduction
7.7.4 MSD Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.7.5 MSD Recent Development
7.8 Foghorn Therapeutics
7.8.1 Foghorn Therapeutics Company Details
7.8.2 Foghorn Therapeutics Business Overview
7.8.3 Foghorn Therapeutics Targeted Protein Degradation Technology Introduction
7.8.4 Foghorn Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.8.5 Foghorn Therapeutics Recent Development
7.9 Dialectic Therapeutics
7.9.1 Dialectic Therapeutics Company Details
7.9.2 Dialectic Therapeutics Business Overview
7.9.3 Dialectic Therapeutics Targeted Protein Degradation Technology Introduction
7.9.4 Dialectic Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.9.5 Dialectic Therapeutics Recent Development
7.10 Accutar Biotech
7.10.1 Accutar Biotech Company Details
7.10.2 Accutar Biotech Business Overview
7.10.3 Accutar Biotech Targeted Protein Degradation Technology Introduction
7.10.4 Accutar Biotech Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.10.5 Accutar Biotech Recent Development
7.11 Cullgen
7.11.1 Cullgen Company Details
7.11.2 Cullgen Business Overview
7.11.3 Cullgen Targeted Protein Degradation Technology Introduction
7.11.4 Cullgen Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.11.5 Cullgen Recent Development
7.12 Bristol-Myers Squibb
7.12.1 Bristol-Myers Squibb Company Details
7.12.2 Bristol-Myers Squibb Business Overview
7.12.3 Bristol-Myers Squibb Targeted Protein Degradation Technology Introduction
7.12.4 Bristol-Myers Squibb Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.12.5 Bristol-Myers Squibb Recent Development
7.13 Monte Rosa Therapeutics
7.13.1 Monte Rosa Therapeutics Company Details
7.13.2 Monte Rosa Therapeutics Business Overview
7.13.3 Monte Rosa Therapeutics Targeted Protein Degradation Technology Introduction
7.13.4 Monte Rosa Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.13.5 Monte Rosa Therapeutics Recent Development
7.14 Proxygen
7.14.1 Proxygen Company Details
7.14.2 Proxygen Business Overview
7.14.3 Proxygen Targeted Protein Degradation Technology Introduction
7.14.4 Proxygen Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.14.5 Proxygen Recent Development
7.15 Dunad Therapeutics
7.15.1 Dunad Therapeutics Company Details
7.15.2 Dunad Therapeutics Business Overview
7.15.3 Dunad Therapeutics Targeted Protein Degradation Technology Introduction
7.15.4 Dunad Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.15.5 Dunad Therapeutics Recent Development
7.16 Astellas
7.16.1 Astellas Company Details
7.16.2 Astellas Business Overview
7.16.3 Astellas Targeted Protein Degradation Technology Introduction
7.16.4 Astellas Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.16.5 Astellas Recent Development
7.17 Origami Therapeutics
7.17.1 Origami Therapeutics Company Details
7.17.2 Origami Therapeutics Business Overview
7.17.3 Origami Therapeutics Targeted Protein Degradation Technology Introduction
7.17.4 Origami Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.17.5 Origami Therapeutics Recent Development
7.18 NEOsphere Biotechnologies
7.18.1 NEOsphere Biotechnologies Company Details
7.18.2 NEOsphere Biotechnologies Business Overview
7.18.3 NEOsphere Biotechnologies Targeted Protein Degradation Technology Introduction
7.18.4 NEOsphere Biotechnologies Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.18.5 NEOsphere Biotechnologies Recent Development
7.19 Ubiquigent
7.19.1 Ubiquigent Company Details
7.19.2 Ubiquigent Business Overview
7.19.3 Ubiquigent Targeted Protein Degradation Technology Introduction
7.19.4 Ubiquigent Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.19.5 Ubiquigent Recent Development
7.20 Kangpu Biopharmaceuticals
7.20.1 Kangpu Biopharmaceuticals Company Details
7.20.2 Kangpu Biopharmaceuticals Business Overview
7.20.3 Kangpu Biopharmaceuticals Targeted Protein Degradation Technology Introduction
7.20.4 Kangpu Biopharmaceuticals Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.20.5 Kangpu Biopharmaceuticals Recent Development
7.21 Ranok Therapeutics
7.21.1 Ranok Therapeutics Company Details
7.21.2 Ranok Therapeutics Business Overview
7.21.3 Ranok Therapeutics Targeted Protein Degradation Technology Introduction
7.21.4 Ranok Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.21.5 Ranok Therapeutics Recent Development
7.22 BeiGene
7.22.1 BeiGene Company Details
7.22.2 BeiGene Business Overview
7.22.3 BeiGene Targeted Protein Degradation Technology Introduction
7.22.4 BeiGene Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.22.5 BeiGene Recent Development
7.23 Hinova Pharma
7.23.1 Hinova Pharma Company Details
7.23.2 Hinova Pharma Business Overview
7.23.3 Hinova Pharma Targeted Protein Degradation Technology Introduction
7.23.4 Hinova Pharma Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.23.5 Hinova Pharma Recent Development
7.24 Haisco Pharmaceutical
7.24.1 Haisco Pharmaceutical Company Details
7.24.2 Haisco Pharmaceutical Business Overview
7.24.3 Haisco Pharmaceutical Targeted Protein Degradation Technology Introduction
7.24.4 Haisco Pharmaceutical Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.24.5 Haisco Pharmaceutical Recent Development
7.25 CTTQ
7.25.1 CTTQ Company Details
7.25.2 CTTQ Business Overview
7.25.3 CTTQ Targeted Protein Degradation Technology Introduction
7.25.4 CTTQ Revenue in Targeted Protein Degradation Technology Business (2021-2026)
7.25.5 CTTQ Recent Development

8 Targeted Protein Degradation Technology Market Dynamics
8.1 Targeted Protein Degradation Technology Industry Trends
8.2 Targeted Protein Degradation Technology Market Drivers
8.3 Targeted Protein Degradation Technology Market Challenges
8.4 Targeted Protein Degradation Technology Market Restraints

9 Research Findings and Conclusion

10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Targeted Protein Degradation Technology Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global Targeted Protein Degradation Technology Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Market Targeted Protein Degradation Technology Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
Table 4. Global Targeted Protein Degradation Technology Revenue (US$ Million) Market Share by Region (2021-2026)
Table 5. Global Targeted Protein Degradation Technology Revenue Share by Region (2021-2026)
Table 6. Global Targeted Protein Degradation Technology Revenue (US$ Million) Forecast by Region (2027-2032)
Table 7. Global Targeted Protein Degradation Technology Revenue Share Forecast by Region (2027-2032)
Table 8. Global Targeted Protein Degradation Technology Market Size by Type (2021-2026) & (US$ Million)
Table 9. Global Targeted Protein Degradation Technology Market Share by Revenue, by Type (2021-2026)
Table 10. Global Targeted Protein Degradation Technology Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 11. Global Targeted Protein Degradation Technology Market Share by Revenue, by Type (2027-2032)
Table 12. Representative Players of Each Type
Table 13. Global Targeted Protein Degradation Technology Market Size by Application (2021-2026) & (US$ Million)
Table 14. Global Targeted Protein Degradation Technology Market Share by Revenue, by Application (2021-2026)
Table 15. Global Targeted Protein Degradation Technology Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 16. Global Targeted Protein Degradation Technology Market Share by Revenue, by Application (2027-2032)
Table 17. New Sources of Growth in Targeted Protein Degradation Technology Applications
Table 18. Global Targeted Protein Degradation Technology Revenue by Players (2021-2026) & (US$ Million)
Table 19. Global Targeted Protein Degradation Technology Market Share by Players (2021-2026)
Table 20. Global Top Targeted Protein Degradation Technology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Protein Degradation Technology as of 2025)
Table 21. Ranking of Global Top Targeted Protein Degradation Technology Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by Targeted Protein Degradation Technology Revenue (CR5 and HHI) & (2021-2026)
Table 23. Global Key Players of Targeted Protein Degradation Technology, Headquarters and Area Served
Table 24. Global Key Players of Targeted Protein Degradation Technology, Product and Application
Table 25. Global Key Players of Targeted Protein Degradation Technology, Date of Entry into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Targeted Protein Degradation Technology Revenue by Company (2021-2026) & (US$ Million)
Table 28. North America Targeted Protein Degradation Technology Market Share by Revenue, by Company (2021-2026)
Table 29. North America Targeted Protein Degradation Technology Market Size by Type (2021-2026) & (US$ Million)
Table 30. North America Targeted Protein Degradation Technology Market Size by Application (2021-2026) & (US$ Million)
Table 31. Europe Targeted Protein Degradation Technology Revenue by Company (2021-2026) & (US$ Million)
Table 32. Europe Targeted Protein Degradation Technology Market Share by Revenue, by Company (2021-2026)
Table 33. Europe Targeted Protein Degradation Technology Market Size by Type (2021-2026) & (US$ Million)
Table 34. Europe Targeted Protein Degradation Technology Market Size by Application (2021-2026) & (US$ Million)
Table 35. China Targeted Protein Degradation Technology Revenue by Company (2021-2026) & (US$ Million)
Table 36. China Targeted Protein Degradation Technology Market Share by Revenue, by Company (2021-2026)
Table 37. China Targeted Protein Degradation Technology Market Size by Type (2021-2026) & (US$ Million)
Table 38. China Targeted Protein Degradation Technology Market Size by Application (2021-2026) & (US$ Million)
Table 39. Japan Targeted Protein Degradation Technology Revenue by Company (2021-2026) & (US$ Million)
Table 40. Japan Targeted Protein Degradation Technology Market Share by Revenue, by Company (2021-2026)
Table 41. Japan Targeted Protein Degradation Technology Market Size by Type (2021-2026) & (US$ Million)
Table 42. Japan Targeted Protein Degradation Technology Market Size by Application (2021-2026) & (US$ Million)
Table 43. Arvinas Company Details
Table 44. Arvinas Business Overview
Table 45. Arvinas Targeted Protein Degradation Technology Product
Table 46. Arvinas Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 47. Arvinas Recent Development
Table 48. C4 Therapeutics Company Details
Table 49. C4 Therapeutics Business Overview
Table 50. C4 Therapeutics Targeted Protein Degradation Technology Product
Table 51. C4 Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 52. C4 Therapeutics Recent Development
Table 53. Kymera Therapeutics Company Details
Table 54. Kymera Therapeutics Business Overview
Table 55. Kymera Therapeutics Targeted Protein Degradation Technology Product
Table 56. Kymera Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 57. Kymera Therapeutics Recent Development
Table 58. Nurix Company Details
Table 59. Nurix Business Overview
Table 60. Nurix Targeted Protein Degradation Technology Product
Table 61. Nurix Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 62. Nurix Recent Development
Table 63. Pfizer Company Details
Table 64. Pfizer Business Overview
Table 65. Pfizer Targeted Protein Degradation Technology Product
Table 66. Pfizer Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 67. Pfizer Recent Development
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Targeted Protein Degradation Technology Product
Table 71. Novartis Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 72. Novartis Recent Development
Table 73. MSD Company Details
Table 74. MSD Business Overview
Table 75. MSD Targeted Protein Degradation Technology Product
Table 76. MSD Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 77. MSD Recent Development
Table 78. Foghorn Therapeutics Company Details
Table 79. Foghorn Therapeutics Business Overview
Table 80. Foghorn Therapeutics Targeted Protein Degradation Technology Product
Table 81. Foghorn Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 82. Foghorn Therapeutics Recent Development
Table 83. Dialectic Therapeutics Company Details
Table 84. Dialectic Therapeutics Business Overview
Table 85. Dialectic Therapeutics Targeted Protein Degradation Technology Product
Table 86. Dialectic Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 87. Dialectic Therapeutics Recent Development
Table 88. Accutar Biotech Company Details
Table 89. Accutar Biotech Business Overview
Table 90. Accutar Biotech Targeted Protein Degradation Technology Product
Table 91. Accutar Biotech Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 92. Accutar Biotech Recent Development
Table 93. Cullgen Company Details
Table 94. Cullgen Business Overview
Table 95. Cullgen Targeted Protein Degradation Technology Product
Table 96. Cullgen Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 97. Cullgen Recent Development
Table 98. Bristol-Myers Squibb Company Details
Table 99. Bristol-Myers Squibb Business Overview
Table 100. Bristol-Myers Squibb Targeted Protein Degradation Technology Product
Table 101. Bristol-Myers Squibb Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 102. Bristol-Myers Squibb Recent Development
Table 103. Monte Rosa Therapeutics Company Details
Table 104. Monte Rosa Therapeutics Business Overview
Table 105. Monte Rosa Therapeutics Targeted Protein Degradation Technology Product
Table 106. Monte Rosa Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 107. Monte Rosa Therapeutics Recent Development
Table 108. Proxygen Company Details
Table 109. Proxygen Business Overview
Table 110. Proxygen Targeted Protein Degradation Technology Product
Table 111. Proxygen Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 112. Proxygen Recent Development
Table 113. Dunad Therapeutics Company Details
Table 114. Dunad Therapeutics Business Overview
Table 115. Dunad Therapeutics Targeted Protein Degradation Technology Product
Table 116. Dunad Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 117. Dunad Therapeutics Recent Development
Table 118. Astellas Company Details
Table 119. Astellas Business Overview
Table 120. Astellas Targeted Protein Degradation Technology Product
Table 121. Astellas Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 122. Astellas Recent Development
Table 123. Origami Therapeutics Company Details
Table 124. Origami Therapeutics Business Overview
Table 125. Origami Therapeutics Targeted Protein Degradation Technology Product
Table 126. Origami Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 127. Origami Therapeutics Recent Development
Table 128. NEOsphere Biotechnologies Company Details
Table 129. NEOsphere Biotechnologies Business Overview
Table 130. NEOsphere Biotechnologies Targeted Protein Degradation Technology Product
Table 131. NEOsphere Biotechnologies Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 132. NEOsphere Biotechnologies Recent Development
Table 133. Ubiquigent Company Details
Table 134. Ubiquigent Business Overview
Table 135. Ubiquigent Targeted Protein Degradation Technology Product
Table 136. Ubiquigent Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 137. Ubiquigent Recent Development
Table 138. Kangpu Biopharmaceuticals Company Details
Table 139. Kangpu Biopharmaceuticals Business Overview
Table 140. Kangpu Biopharmaceuticals Targeted Protein Degradation Technology Product
Table 141. Kangpu Biopharmaceuticals Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 142. Kangpu Biopharmaceuticals Recent Development
Table 143. Ranok Therapeutics Company Details
Table 144. Ranok Therapeutics Business Overview
Table 145. Ranok Therapeutics Targeted Protein Degradation Technology Product
Table 146. Ranok Therapeutics Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 147. Ranok Therapeutics Recent Development
Table 148. BeiGene Company Details
Table 149. BeiGene Business Overview
Table 150. BeiGene Targeted Protein Degradation Technology Product
Table 151. BeiGene Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 152. BeiGene Recent Development
Table 153. Hinova Pharma Company Details
Table 154. Hinova Pharma Business Overview
Table 155. Hinova Pharma Targeted Protein Degradation Technology Product
Table 156. Hinova Pharma Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 157. Hinova Pharma Recent Development
Table 158. Haisco Pharmaceutical Company Details
Table 159. Haisco Pharmaceutical Business Overview
Table 160. Haisco Pharmaceutical Targeted Protein Degradation Technology Product
Table 161. Haisco Pharmaceutical Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 162. Haisco Pharmaceutical Recent Development
Table 163. CTTQ Company Details
Table 164. CTTQ Business Overview
Table 165. CTTQ Targeted Protein Degradation Technology Product
Table 166. CTTQ Revenue in Targeted Protein Degradation Technology Business (2021-2026) & (US$ Million)
Table 167. CTTQ Recent Development
Table 168. Targeted Protein Degradation Technology Market Trends
Table 169. Targeted Protein Degradation Technology Market Drivers
Table 170. Targeted Protein Degradation Technology Market Challenges
Table 171. Targeted Protein Degradation Technology Market Restraints
Table 172. Research Programs/Design for This Report
Table 173. Key Data Information from Secondary Sources
Table 174. Key Data Information from Primary Sources

List of Figures
Figure 1. Targeted Protein Degradation Technology Product Picture
Figure 2. Global Targeted Protein Degradation Technology Market Share by Type: 2025 vs 2032
Figure 3. PROTAC Features
Figure 4. Molecular Glues Features
Figure 5. Other Ubiquitin-Proteasome System Technologies Features
Figure 6. Lysosomal System Technologies Features
Figure 7. Global Targeted Protein Degradation Technology Market Share by Application: 2025 vs 2032
Figure 8. Prostate Cancer
Figure 9. Breast Cancer
Figure 10. Lymphoma
Figure 11. Others
Figure 12. Targeted Protein Degradation Technology Report Years Considered
Figure 13. Global Targeted Protein Degradation Technology Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 14. Global Targeted Protein Degradation Technology Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Targeted Protein Degradation Technology Market Share by Revenue, by Region: 2021 vs 2025
Figure 16. North America Targeted Protein Degradation Technology Revenue (US$ Million) Growth Rate (2021-2032)
Figure 17. Europe Targeted Protein Degradation Technology Revenue (US$ Million) Growth Rate (2021-2032)
Figure 18. China Targeted Protein Degradation Technology Revenue (US$ Million) Growth Rate (2021-2032)
Figure 19. Japan Targeted Protein Degradation Technology Revenue (US$ Million) Growth Rate (2021-2032)
Figure 20. Global Targeted Protein Degradation Technology Market Share by Players in 2025
Figure 21. Global Top Targeted Protein Degradation Technology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Protein Degradation Technology as of 2025)
Figure 22. The Top 10 and 5 Players Market Share by Targeted Protein Degradation Technology Revenue in 2025
Figure 23. North America Targeted Protein Degradation Technology Market Share by Type (2021-2026)
Figure 24. North America Targeted Protein Degradation Technology Market Share by Application (2021-2026)
Figure 25. Europe Targeted Protein Degradation Technology Market Share by Type (2021-2026)
Figure 26. Europe Targeted Protein Degradation Technology Market Share by Application (2021-2026)
Figure 27. China Targeted Protein Degradation Technology Market Share by Type (2021-2026)
Figure 28. China Targeted Protein Degradation Technology Market Share by Application (2021-2026)
Figure 29. Japan Targeted Protein Degradation Technology Market Share by Type (2021-2026)
Figure 30. Japan Targeted Protein Degradation Technology Market Share by Application (2021-2026)
Figure 31. Arvinas Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 32. C4 Therapeutics Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 33. Kymera Therapeutics Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 34. Nurix Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 35. Pfizer Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 36. Novartis Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 37. MSD Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 38. Foghorn Therapeutics Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 39. Dialectic Therapeutics Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 40. Accutar Biotech Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 41. Cullgen Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 42. Bristol-Myers Squibb Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 43. Monte Rosa Therapeutics Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 44. Proxygen Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 45. Dunad Therapeutics Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 46. Astellas Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 47. Origami Therapeutics Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 48. NEOsphere Biotechnologies Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 49. Ubiquigent Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 50. Kangpu Biopharmaceuticals Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 51. Ranok Therapeutics Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 52. BeiGene Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 53. Hinova Pharma Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 54. Haisco Pharmaceutical Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 55. CTTQ Revenue Growth Rate in Targeted Protein Degradation Technology Business (2021-2026)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed